# reload+after+2024-01-20 19:47:15.826062
address1§2450 Holcombe Boulevard
address2§Suite X
city§Houston
state§TX
zip§77021
country§United States
phone§832 834 6992
website§https://www.salariuspharma.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds and Cancer Prevention and Research Institute of Texas for product development activities. Salarius Pharmaceuticals, Inc. is headquartered in Houston, Texas.
fullTimeEmployees§12
companyOfficers§[{'maxAge': 1, 'name': 'Mr. David J. Arthur M.B.A.', 'age': 60, 'title': 'CEO, President & Director', 'yearBorn': 1963, 'fiscalYear': 2022, 'totalPay': 729575, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Mark J. Rosenblum CPA', 'age': 70, 'title': 'Executive VP of Finance & CFO', 'yearBorn': 1953, 'fiscalYear': 2022, 'totalPay': 409975, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Nadeem Q. Mirza M.D., M.P.H.', 'title': 'Senior Vice President of Clinical Development', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Daniela Y. Santiesteban', 'title': 'Director of Targeted Protein Degradation Program', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§0.96
currency§USD
dateShortInterest§1702598400
forwardEps§-3.02
exchange§NCM
quoteType§EQUITY
shortName§Salarius Pharmaceuticals, Inc.
longName§Salarius Pharmaceuticals, Inc.
firstTradeDateEpochUtc§1422541800
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§f7c5d494-3e4a-33bc-9704-e2b0ec3dd19f
gmtOffSetMilliseconds§-18000000
targetHighPrice§3.25
targetLowPrice§3.0
targetMeanPrice§3.13
targetMedianPrice§3.13
recommendationMean§3.0
recommendationKey§hold
numberOfAnalystOpinions§2
quickRatio§3.267
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
